Giuseppina Brancaccio

List of Publications by Year
in descending order

54	1,526	331538 21	315616 38
papers	citations	h-index	g-index

55	55	55	2411
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathogens and Global Health, 2023, 117, 181-189.	1.0	9
2	A prospective study of directâ€acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology, 2022, 76, 220-232.	3.6	12
3	CD8⁺ T cells specific to apoptosisâ€associated epitopes are expanded in patients with chronic HBV infection and fibrosis. Liver International, 2021, 41, 470-481.	1.9	7
4	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.4	2
5	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. Microorganisms, 2021, 9, 752.	1.6	10
6	Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. BMC Infectious Diseases, 2021, 21, 413.	1.3	12
7	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. Infectious Diseases, 2020, 52, 557-562.	1.4	8
8	Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant settingâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 484-484.	1.9	1
9	Prophylaxis of Hepatitis B Virus (HBV) Re-Infection in Liver Transplantation: Is the Reappearance of Hepatitis B Surface Antigen (HBsAg) Significant?. Annals of Transplantation, 2020, 25, e920969.	0.5	5
10	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. Antiviral Therapy, 2020, 25, 73-81.	0.6	2
11	Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005â€"2015 systematic review. BMC Infectious Diseases, 2019, 19, 653.	1.3	64
12	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells, 2019, 8, 666.	1.8	13
13	Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. International Journal of Antimicrobial Agents, 2019, 54, 697-701.	1.1	11
14	Sunscreen ingredients in plasma: a threat for drugâ€"drug interactions and toxicity among patients living with HIV?. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 775-778.	1.5	3
15	Realâ€life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver International, 2019, 39, 1852-1859.	1.9	31
16	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. Antiviral Therapy, 2019, 24, 485-493.	0.6	5
17	Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving longâ€term tenofovir or entecavir. Alimentary Pharmacology and Therapeutics, 2019, 49, 1071-1076.	1.9	35
18	Hepatitis C late relapse in patients with directly acting antiviralâ€related sustained virological response at week 12. Liver International, 2019, 39, 844-853.	1.9	4

#	Article	IF	Citations
19	AISF position paper on HCV in immunocompromised patients. Digestive and Liver Disease, 2019, 51, 10-23.	0.4	5
20	The present profile of chronic hepatitis B virus infection highlights future challenges. Digestive and Liver Disease, 2019, 51, 438-442.	0.4	17
21	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. Liver International, 2019, 39, 484-493.	1.9	9
22	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. European Journal of Internal Medicine, 2018, 53, 79-84.	1.0	69
23	Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. Clinical Gastroenterology and Hepatology, 2018, 16, 977-978.	2.4	12
24	Virological patterns of HCV patients with failure to interferonâ€free regimens. Journal of Medical Virology, 2018, 90, 942-950.	2.5	14
25	Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). Infectious Diseases, 2018, 50, 125-132.	1.4	4
26	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. Journal of Hepatology, 2018, 68, 597-600.	1.8	28
27	Hepatitis C Virus Clearance in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 85-91.	1.3	6
28	Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy. Medicine (United States), 2018, 97, e11307.	0.4	3
29	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.4	41
30	Forecasting Hepatitis C liver disease burden on realâ€life data. Does the hidden iceberg matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	1.9	33
31	Multiclass <scp>HCV</scp> resistance to directâ€acting antiviral failure in realâ€life patients advocates for tailored secondâ€line therapies. Liver International, 2017, 37, 514-528.	1.9	84
32	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. Digestive and Liver Disease, 2017, 49, 1022-1028.	0.4	19
33	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. Digestive and Liver Disease, 2017, 49, 197-201.	0.4	5
34	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a crossâ€sectional multicenter study. Journal of Medical Virology, 2017, 89, 2138-2143.	2.5	13
35	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
36	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. European Journal of Internal Medicine, 2017, 38, 68-72.	1.0	23

#	Article	IF	Citations
37	Hepatitis delta infection in Italian patients: towards the end of the story?. Infection, 2017, 45, 277-281.	2.3	34
38	Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population. PLoS ONE, 2017, 12, e0172101.	1.1	24
39	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS ONE, 2017, 12, e0172159.	1.1	42
40	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	1.1	37
41	Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. Digestive and Liver Disease, 2016, 48, 1066-1071.	0.4	34
42	Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Therapeutics and Clinical Risk Management, 2015, 11, 1603.	0.9	12
43	Interleukinâ€28B genetic variants in untreated Italian <scp>HCV</scp>â€infected patients: a multicentre study. Liver International, 2015, 35, 482-488.	1.9	4
44	Identification of naÃ¯ve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. Journal of Hepatology, 2014, 60, 16-21.	1.8	25
45	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naÃ¯ve patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 818-825.	0.4	8
46	Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections. Digestive and Liver Disease, 2014, 46, 62-66.	0.4	14
47	Individualized Treatment of Genotype 1 NaÃ¯ve Patients: An Italian Multicenter Field Practice Experience. PLoS ONE, 2014, 9, e110284.	1.1	5
48	Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis. Liver International, 2013, 33, 834-842.	1.9	24
49	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. Journal of Hepatology, 2012, 56, 1254-1258.	1.8	29
50	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. Gastroenterology, 2012, 143, 963-973.e9.	0.6	308
51	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Digestive and Liver Disease, 2011, 43, 875-80.	0.4	23
52	Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis?. World Journal of Gastroenterology, 2011, 17, 1606.	1.4	5
53	Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine, 2009, 27, 3373-3375.	1.7	39
54	Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology, 2006, 44, 713-720.	3.6	222